Onco-Innovations Stock Price, News & Analysis

Onco-Innovations' (ONNVF) subsidiary Inka Health has published a groundbreaking study in JAMA Network Open, sponsored by Roche, addressing methodological gaps in real-world oncology research. The study, titled 'Quantitative Bias Analysis for the Assessment of Bias in Comparisons between Synthetic Control Arms,' introduces Q-BASEL, a novel approach to improve the validity of clinical comparisons from real-world data.

The research, led by Inka Health co-founder Alind Gupta, conducted 15 treatment comparisons in advanced non-small cell lung cancer (aNSCLC) using real-world patient data. The study demonstrated that applying Quantitative Bias Analysis (QBA) significantly improved the alignment between real-world emulations and original randomized trial outcomes.

This methodology will be integrated into Inka's SynoGraph platform, enhancing support for pharmaceutical partners in optimizing real-world evidence strategies, particularly in scenarios where traditional randomized trials are not feasible.

Onco-Innovations (OTCQB:ONNVF) announces its subsidiary Inka Health has completed analytical work for AstraZeneca Canada under a service agreement from September 2024. The project focuses on advancing pharmaceutical evidence generation and real-world data analysis.

Two research studies will be presented at ISPOR 2025 in Montréal: The first study explores methodologies to enhance real-world evidence credibility through transportability analyses, while the second evaluates RWE utilization in Canadian drug regulatory submissions.

The findings are being integrated into Inka Health's proprietary analytics platform, SynoGraph, which incorporates advanced causal inference techniques. The presentations are scheduled for May 16, 2025, from 9:00-11:30 AM ET at the conference.

Onco-Innovations (ONNVF) has reported positive results from a December 2021 University of Alberta study on its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound used in combination with radiation therapy. The study focused on mice with colorectal cancer tumors, divided into three treatment groups receiving different combinations of treatments over 24 days.

The key finding revealed that the PNKP technology demonstrated effective cancer cell targeting while maintaining a low toxicity profile, even at therapeutic doses. Notably, no significant toxicity signs, including weight loss, were observed in any treatment group, including those receiving PNKP inhibitor-loaded nanoparticles with radiation.

This development is particularly significant as it suggests potential for developing safer cancer treatments with fewer side effects. The technology's minimal toxicity in preclinical animal models aligns with Health Canada's rigorous testing requirements for drug safety assessment.

Onco-Innovations (OTCQB:ONNVF) has announced the extension of its marketing engagement with MCS Market Communication Service GmbH through May 31, 2025. The company has allocated CAD 600,000 for the extended services, which include campaign creation, marketing materials production, and research and analytics.

The marketing services will be delivered through digital channels, specifically Google Ads and native advertising. The agreement will continue until the specified end date or until the budget is exhausted. No securities were issued as compensation for these services.

Onco-Innovations (OTCQB:ONNVF) has provided an update on its use of proceeds from recent fundraising activities. The company successfully raised the maximum offering of $2.5 million through its November 2024 Prospectus, plus an additional $1.29 million since then.

The company has significantly increased its focus on investor relations activities, particularly in Germany, to enhance market visibility and counter challenging conditions in Canadian capital markets. Operating expenses have exceeded initial projections due to increased activity, including costs related to the Inka Health acquisition, fundraising, and regulatory interactions.

Research and development spending has also increased substantially, driven by faster-than-expected equity financing and the Inka acquisition. This includes approximately $180,000 invested in developing Synograph and its core AI Model since the Inka acquisition.

Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy was featured in an exclusive interview on Conversations That Matter, discussing the company's developments in cancer treatment and AI integration. The interview highlighted:

The company's focus on developing novel treatment for colorectal cancer and solid tumors, utilizing precision medicine to enhance traditional therapies. Their proprietary technology, developed by University of Alberta Cancer Institute scientists, employs targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue.

The interview also covered their recent acquisition of Inka Health AI, which is developing AI tools to optimize patient identification and enhance clinical trial efficacy. The company maintains strategic partnerships with Quantify Research and AstraZeneca Canada to advance precision medicine approaches in cancer therapeutic development.

Onco-Innovations (OTCQB:ONNVF) subsidiary Inka Health has published a groundbreaking study protocol in medRxiv focusing on AI-generated synthetic patient models for oncology research. The study, titled 'ECLIPSE', leverages advanced machine learning to create synthetic patient data, particularly beneficial for rare cancer research where traditional patient data is scarce.

Led by Dr. Winson Cheung, Medical Advisor at Inka Health and Professor at the University of Calgary, alongside Inka Health co-founders Dr. Paul Arora and Dr. Alind Gupta, the research aims to develop synthetic patient cohorts using AI technology. The initiative utilizes Inka's proprietary AI platform, SynoGraph, to enhance patient stratification and improve clinical trial efficiency.

The technology focuses on generating comparator arms for trials, addressing a critical challenge in rare cancer research where randomizing patients to control groups is often unfeasible. This approach aims to accelerate drug development and regulatory processes in the pharmaceutical and biotech industries.

Onco-Innovations has announced that its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound has demonstrated enhanced PNKP inhibitor delivery with minimal toxicity. A June 2021 study by the University of Alberta revealed that the technology was well-tolerated at therapeutic doses in mice with colorectal cancer, showing no signs of toxicity such as weight loss or adverse effects. This formulation, tested as a targeted therapy for PTEN-deficient colorectal cancer, showed promising results in both in vitro and in vivo evaluations.

The study involved treating mice with the PKNP nanoparticle formulation (NP/A83) over a 22-day period, while a control group received placebo injections. Both biochemical and histopathological examinations confirmed the absence of toxicity in major organs. Dose-escalating toxicity studies on healthy CD-1 mice indicated that both free and nano-encapsulated PNKP inhibitors were safe at doses of ≤50 mg/kg. The findings suggest potential for developing safer and more effective cancer treatments with fewer side effects.

Thomas O'Shaughnessy, CEO, emphasized the technology's promise for future therapeutic development due to its low toxicity profile, laying a foundation for continued research and development.

Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health, filed a provisional patent application with the USPTO for SynoGraph, its next-generation AI platform, on January 28, 2025. The application, titled 'Method and System for Causal Graph Generation and Analysis,' aims to protect their AI-driven precision medicine approach.

SynoGraph utilizes AI-powered causal inference to identify cancer patients likely to respond to specific treatments. The platform integrates various medical data types including genomics, transcriptomics, and proteomics to uncover insights for treatment decisions and clinical trial design. The technology is expected to enhance Onco's drug research initiatives by potentially streamlining trial design and patient selection, which could reduce development costs and improve patient outcomes.